What Does the Future Hold for Patients With Nonalcoholic Steatohepatitis: Diagnostic Strategies and Treatment Options in 2021 and Beyond?

Naim Alkhouri, Monica Tincopa, Rohit Loomba, Stephen A. Harrison – 8 September 2021 – Nonalcoholic steatohepatitis (NASH) can progress to cirrhosis and its complications, including hepatocellular carcinoma. Given that the majority of patients with NASH are asymptomatic, developing screening strategies to identify those individuals at risk for progressive NASH remains a highly unmet need.

Magnetic resonance elastography plus Fibrosis‐4 versus FibroScan–aspartate aminotransferase in detection of candidates for pharmacological treatment of NASH‐related fibrosis

Nobuharu Tamaki, Kento Imajo, Suzanne Sharpton, Jinho Jung, Nobuyoshi Kawamura, Masato Yoneda, Mark A. Valasek, Cynthia Behling, Claude B. Sirlin, Atsushi Nakajima, Rohit Loomba – 7 September 2021

Research methodologies to address clinical unmet needs and challenges in alcohol‐associated liver disease

Ashwani K. Singal, Paul Kwo, Allison Kwong, Suthat Liangpunsakul, Alexandre Louvet, Pranoti Mandrekar, Craig McClain, Jessica Mellinger, Gyongyi Szabo, Norah Terrault, Mark Thursz, Gerald S. Winder, W. Ray Kim, Vijay H. Shah – 7 September 2021 – Alcohol‐associated liver disease (ALD) is emerging worldwide as the leading cause of liver‐related morbidity, mortality, and indication for liver transplantation.

Subscribe to